TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

New phase 1 trial NCT06917079 posted by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics): "BBO-11818 in Adult Subjects With KRAS Mutant Cancer". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 98 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

New phase 1 trial NCT06625775 posted by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics): "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 77 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.